News
Hygieia welcomes Heineman as Vice President of Business Development
Heineman brings over 30 years of expertise in strategic leadership, operations, and business development in the biopharmaceutical and medical device industries. She is an internationally known member of the diabetes community with a track record of opening new markets for diabetes technology.
Read MoreHygieia Extends Series B Round to $22 Million with Participation from Strategic Investors
Livonia, Mich., May 2, 2023 – Hygieia, a digital therapeutics company for insulin therapy, is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners. Hygieia is the maker of d-Nav®, the only FDA-cleared technology to autonomously adjust insulin dose recommendations to…
Read MoreHygieia Expands to Arizona, as Endocrinology Associates, PA, Joins d-Nav® Insulin Management Clinical Partnership Program
Partnership model gives physicians better tools for insulin therapy and offers new reimbursement opportunities Livonia, Michigan, Jan. 10, 2023 — Hygieia, a provider of digital therapeutics for insulin management, has added Endocrinology Associates, PA, in Scottsdale and Chandler, AZ, as a clinical partner. This makes Hygieia’s d-Nav® autonomous insulin therapy service available to patients with type…
Read MoreHygieia adds to team, continues rapid, national expansion of its d-Nav® Insulin Management Program
Demand grows for d-Nav Technology, the first FDA-cleared app to autonomously adjust insulin doses Livonia, Michigan, Dec. 13, 2022 — Hygieia, a digital therapeutics company, has relocated and expanded its headquarters to accommodate additional staff as it continues significant growth and pursues partnerships with endocrinology practices across the United States. Hygieia’s expansion is in response to increased…
Read More
Hygieia adds clinical partners in New York and North Carolina to its
d-Nav® Insulin Management Program
Partnership model increases doctors’ ability to coordinate patients’ insulin therapy andoffers new reimbursement opportunities Livonia, Mich., Sept. 12, 2022 — Hygieia, a provider of digital therapeutics for insulin management, has added Endocrine Associates of West Village P.C. in Manhattan and Long Island City, NY, and Physicians East in Greenville, NC, as clinical partners. The partnerships are…
Read MoreHygieia adds Metro Detroit Endocrinology Center as clinical partner for its d-Nav® Insulin Management Program
New partnership expands availability of d-Nav program for underserved Livonia, Mich., August 30, 2022 — Hygieia, a provider of digital therapeutics for insulin management, has added Metro Detroit Endocrinology Center in Dearborn as a clinical partner. The partnership extends Hygieia’s d-Nav® network and makes autonomous insulin therapy service available for an underserved population. The unique…
Read MoreDiabetes Technology Leader and Global Business Executive Doug Lawrence Joins Hygieia as CEO
Livonia, Michigan, Aug. 23, 2022 – Hygieia, a digital therapeutics company for insulin therapy, has appointed Doug Lawrence its chief executive officer, responsible for leading operations, development, and global growth of the company and its d-Nav® Insulin Management Program. Lawrence brings three decades of medical technology leadership to his new role at Hygieia, including significant experience…
Read MoreHygieia announces new CPT codes for autonomous insulin dose titration
Livonia, Mich., July 26, 2022 – Hygieia, a digital therapeutics company for insulin therapy, announces the American Medical Association (AMA) CPT Editorial Panel has approved two new Category III codes for autonomous insulin dose titration, which can be used for Hygieia’s d-Nav® Technology. d-Nav is the first FDA-cleared technology to autonomously adjust insulin dose recommendations…
Read MoreHygieia Advances its Global Business Development Activities with d-Nav® Program in Israel
Livonia, Michigan, June 23, 2022 – Hygieia, a digital therapeutics company for insulin therapy, has successfully licensed its d-Nav insulin management technology to Movement Group, a provider of health and wellness programs to integrated health delivery networks in Israel. The agreement is part of an accelerated strategy to expand its d-Nav insulin titration technology globally. d-Nav…
Read MoreHygieia Launches d-Nav® Clinical Partnership Program at AACE Annual Meeting
SAN DIEGO, Calif.–(BUSINESS WIRE)–Hygieia, a digital therapeutics company, today announced the official launch of its d-Nav Clinical Partnership Program for endocrinology practices treating patients with type 2 diabetes. The d-Nav Clinical Partnership Program is turnkey. It provides patients with access to d-Nav autonomous insulin dose technology and a clinical support team. For clinical partners, the d-Nav…
Read More